Agios

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Agios and other ETFs, options, and stocks.

About AGIO

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. 

CEO
Brian M. Goff
CEOBrian M. Goff
Employees
540
Employees540
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2007
Founded2007
Employees
540
Employees540

AGIO Key Statistics

Market cap
2.19B
Market cap2.19B
Price-Earnings ratio
-4.88
Price-Earnings ratio-4.88
Dividend yield
Dividend yield
Average volume
1.42M
Average volume1.42M
High today
$34.31
High today$34.31
Low today
$32.33
Low today$32.33
Open price
$32.74
Open price$32.74
Volume
1.09M
Volume1.09M
52 Week high
$46.00
52 Week high$46.00
52 Week low
$22.24
52 Week low$22.24

Stock Snapshot

As of today, Agios(AGIO) shares are valued at $34.21. The company's market cap stands at 2.19B, with a P/E ratio of -4.88.

As of 2026-08-13, Agios(AGIO) stock has fluctuated between $32.33 and $34.31. The current price stands at $34.21, placing the stock +5.8% above today's low and -0.3% off the high.

Agios(AGIO) shares are trading with a volume of 1.09M, against a daily average of 1.42M.

In the last year, Agios(AGIO) shares hit a 52-week high of $46.00 and a 52-week low of $22.24.

In the last year, Agios(AGIO) shares hit a 52-week high of $46.00 and a 52-week low of $22.24.

AGIO News

Simply Wall St 4d
Agios Pharmaceuticals In Focus On Earnings As Undervalued Narrative Holds

Advertisement Earnings event puts Agios Pharmaceuticals stock in focus Agios Pharmaceuticals (AGIO) reported second quarter 2026 results on July 30, with reve...

Agios Pharmaceuticals In Focus On Earnings As Undervalued Narrative Holds
Simply Wall St 7d
How Surging Revenue With Ongoing Losses Will Impact Agios Pharmaceuticals Investors

In the second quarter of 2026, Agios Pharmaceuticals, Inc. reported revenue of US$44.75 million versus US$12.46 million a year earlier, with net loss decreasing...

How Surging Revenue With Ongoing Losses Will Impact Agios Pharmaceuticals Investors

Analyst ratings

70%

of 10 ratings
Buy
70%
Hold
30%
Sell
0%

People also own

Based on the portfolios of people who own AGIO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.